Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 plus amlodipine vs LCZ696 alone in grade 1–2 hypertension (Japan)
jRCT2031230703Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of sacubitril + valsartan and amlodipine in essential hypertension (8 arms), sponsored by Novartis. Primary endpoint: Change from baseline to Week 8 in mean sitting systolic blood pressure. Started Apr 2024; status: active, not recruiting.
02
Drugs
sacubitril + valsartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2031230703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230703.